Synova Healthcare Increases Distribution of Fem-V(TM) Through Publix Super Markets, Inc.

MEDIA, Penn. -- Synova Healthcare, Inc., a subsidiary of Synova Healthcare Group, Inc. (OTCBB: SNVH), has increased its distribution of Fem-V[TM] through Publix Super Markets, Inc., the largest and fastest growing employee-owned supermarket chain in the U.S.

Lakeland, Florida-based Publix has 884 stores in Florida, Georgia, South Carolina, Alabama and Tennessee. The Company was recently named the No. 1 supermarket pharmacy for customer satisfaction in the nation by Wilson Health Information, a leading consumer research firm, for the fourth consecutive year.

The distribution expansion announced by Synova pertains to the Company's new non-invasive diagnostic test, Fem-V[TM]. Fem-V[TM] was developed to assist women in diagnosing the presence of vaginal infections from the privacy of their own home. The product also assists women in determining whether they can consider an over-the-counter treatment or should seek professional care for their symptoms. Publix plans to have the product on its shelves in early November, 2006.

Stephen E. King, Chairman and CEO of Synova Healthcare Group, Inc., said: "We are pleased to announce Fem-V[TM]'s distribution through Publix. Publix represents another very important point of retail distribution for Fem-V[TM] and increases product access for our customers. Synova remains dedicated to delivering innovative healthcare products focused in women's healthcare, and offering healthcare solutions through every stage of a woman's reproductive life."

About Synova Healthcare Group, Inc.

Synova Healthcare Group, Inc., through its subsidiaries Synova Healthcare, Inc. and Synova Pre-Natal Healthcare, Inc., is focused on the development, distribution, marketing and sale of non-invasive medical diagnostic tests that allow consumers and healthcare professionals to rapidly and accurately diagnose and monitor the onset of certain medical conditions. The Company's efforts are currently concentrated in the women's healthcare sector. Its goal is to supplant traditional, more invasive, and costly diagnostic testing techniques, such as blood or serum assays, by offering rapid, non-invasive test alternatives. The Company's products afford consumers discreet use from home, and allow clinicians to offer streamlined healthcare services by providing rapid and accurate test results from within their offices. For further information, please visit the company's website at www.synovahealthcare.com.

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends", "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. Such risk factors are discussed in the Company's Registration Statement on Form SB-2 (File No. 333-123498), as amended, as declared effective by the Securities and Exchange Commission on May 22, 2006, as well as in other periodic reports and filings with the Commission. There can be no assurance that such factors will not affect the accuracy of such forward-looking statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information set forth in this Press Release including such forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy; nor will there be any sale of securities of Synova Healthcare Group, Inc. in any state where such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of those states.